Huishou Fan
YOU?
Author Swipe
View article: Unravelling the physiological and molecular mechanisms of leaf color change in Acer griseum through multi-omics analysis
Unravelling the physiological and molecular mechanisms of leaf color change in Acer griseum through multi-omics analysis Open
Paperbark maple (Acer griseum), an endemic and endangered wild plant in China, has red-colored autumn leaves of high ornamental and garden application value. Leaf color change serves as a crucial indicator for evaluating garden tree aesthe…
View article: Data from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Data from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing Open
Purpose:In multiple myeloma (MM), therapy-induced clonal evolution is associated with treatment resistance and is one of the most important hindrances toward a cure for MM. To further understand the molecular mechanisms controlling the clo…
View article: Supplementary Data 2 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Supplementary Data 2 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing Open
Supplemental table 1-15.
View article: Supplementary Data 1 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Supplementary Data 1 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing Open
Supplementary figure 1-9
View article: Data from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Data from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing Open
Purpose:In multiple myeloma (MM), therapy-induced clonal evolution is associated with treatment resistance and is one of the most important hindrances toward a cure for MM. To further understand the molecular mechanisms controlling the clo…
View article: Supplementary Data 2 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Supplementary Data 2 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing Open
Supplemental table 1-15.
View article: Supplementary Data 1 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Supplementary Data 1 from Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing Open
Supplementary figure 1-9
View article: Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing
Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in Minimal Residual Clones in Multiple Myeloma through Single-Cell Sequencing Open
Purpose: In multiple myeloma (MM), therapy-induced clonal evolution is associated with treatment resistance and is one of the most important hindrances toward a cure for MM. To further understand the molecular mechanisms controlling the cl…
View article: MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities
MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities Open
Not available.
View article: Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poor prognosis in myeloma
Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poor prognosis in myeloma Open
Background: Deeper depth of response (DpR) after induction therapy, especially gain of negative minimal residual disease (MRD), has been linked to prolonged survival in multiple myeloma (MM). However, flow-MRD examination focuses on the nu…
View article: Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma Open
Background The duration of response to treatment is a major prognostic factor, and early relapse (ER) strongly predicts inferior survival in multiple myeloma (MM). However, the definitions of ER in MM vary from study to study and how to dy…
View article: The age-dependent changes in risk weights of the prognostic factors for multiple myeloma
The age-dependent changes in risk weights of the prognostic factors for multiple myeloma Open
Multiple myeloma is a highly heterogenous plasma cell malignancy, commonly seen in older patients. Age is one of the important prognostic factors. However, nearly all the prognostic staging systems are based on clinical trials, where patie…
View article: Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation Open
Autologous stem cell transplantation (ASCT) is the standard therapy for patients with transplant-eligible multiple myeloma (TEMM). However, the ideal depth of response required before ASCT and the impact of residual tumor cells in the stem…
View article: FIGURE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
FIGURE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
The impact of ASCT and early MRD status on prognosis. Impact of early MRD-negative status on PFS (A) and impact of early MRD-negative status on OS (B); impact of ASCT by different MRD status on PFS (C); impact of ASCT …
View article: FIGURE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
FIGURE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
The impact of ASCT and early MRD status on prognosis. Impact of early MRD-negative status on PFS (A) and impact of early MRD-negative status on OS (B); impact of ASCT by different MRD status on PFS (C); impact of ASCT …
View article: TABLE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
TABLE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Multivariate analyses of PFS and OS in 407 patients with transplant-eligible myeloma
View article: TABLE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
TABLE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Patient and treatment characteristics by MRD status after induction treatment
View article: Data from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Data from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Attaining undetectable minimal residual disease (MRD) is the current therapeutic goal for multiple myeloma. But there is a current lack of data regarding the clinical benefit of autologous stem cell transplantation (ASCT) for patients with…
View article: Figure S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Figure S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
The workflow of patient selection in this study.
View article: Figure S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Figure S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
The workflow of patient selection in this study.
View article: FIGURE 3 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
FIGURE 3 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
The impact of ASCT on MRD status duration among early MRD-negative patients: impact of ASCT on MRD-negative status duration (A); multivariate analysis for MRD-negative duration (B); impact of continued MRD-negative status (≥2…
View article: Table S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Table S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Patient Characteristics, Treatments, and MRD detective methods: ASCT vs. Non-ASCT
View article: Figure S3 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Figure S3 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
The prognostic impact of ASCT and early MRD status by molecular risk groups
View article: FIGURE 4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
FIGURE 4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Impact of longitudinal MRD status before and after ASCT on prognosis: impact of MRD status at ASCT+3 on PFS (A), the impact of MRD status at ASCT+3 on OS (B); the distribution of different MRD status before and after ASCT (
View article: TABLE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
TABLE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Patient and treatment characteristics by MRD status after induction treatment
View article: FIGURE 4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
FIGURE 4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Impact of longitudinal MRD status before and after ASCT on prognosis: impact of MRD status at ASCT+3 on PFS (A), the impact of MRD status at ASCT+3 on OS (B); the distribution of different MRD status before and after ASCT (
View article: Figure S4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Figure S4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Subgroup analyses for prognostic impact of ASCT
View article: Table S2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Table S2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
The impact of ASCT on PFS and OS among all patients
View article: FIGURE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
FIGURE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
Subgroup analyses for impact of ASCT among early MRD-negative patients on PFS (A), OS (B). Abnormal LDH level: >247 U/L; ASCT: autologous stem cell transplant; early MRD-negative: achieving MRD-negative after induction treatm…
View article: Table S2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Table S2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment Open
The impact of ASCT on PFS and OS among all patients